Roivant Sciences (NASDAQ:ROIV) Shares Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of Roivant Sciences Ltd. (NASDAQ:ROIV). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Roivant Sciences stock on October 31st. The trade occurred in the Representative’s “CHARLES SCHWAB 401K > SCHWAB 893” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Roivant Sciences Stock Up 0.0%

Roivant Sciences stock opened at $20.87 on Thursday. The firm has a 50 day moving average price of $18.04 and a 200-day moving average price of $13.87. Roivant Sciences Ltd. has a twelve month low of $8.73 and a twelve month high of $21.35. The company has a market capitalization of $14.51 billion, a P/E ratio of -37.27 and a beta of 1.23.

Insider Buying and Selling at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 539,650 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $20.51, for a total value of $11,068,221.50. Following the completion of the transaction, the insider directly owned 33,653,756 shares in the company, valued at approximately $690,238,535.56. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Allen Gold sold 1,300,000 shares of the stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $20.23, for a total value of $26,299,000.00. Following the completion of the transaction, the director directly owned 18,047,727 shares in the company, valued at approximately $365,105,517.21. This represents a 6.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 8,483,561 shares of company stock worth $143,557,750 over the last three months. 10.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Danske Bank A S purchased a new position in Roivant Sciences during the third quarter worth about $138,000. XTX Topco Ltd purchased a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $1,067,000. Alyeska Investment Group L.P. boosted its position in shares of Roivant Sciences by 326.7% during the 3rd quarter. Alyeska Investment Group L.P. now owns 494,455 shares of the company’s stock valued at $7,481,000 after acquiring an additional 378,589 shares during the last quarter. Utah Retirement Systems grew its holdings in shares of Roivant Sciences by 3.0% during the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after purchasing an additional 600 shares in the last quarter. Finally, Voleon Capital Management LP bought a new position in shares of Roivant Sciences in the third quarter worth approximately $1,461,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ROIV. HC Wainwright increased their price objective on Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, September 18th. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partners reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Roivant Sciences in a report on Tuesday, November 11th. Weiss Ratings upgraded shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Finally, Citigroup boosted their target price on shares of Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $22.56.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.